Objective: To determine the efficacy of 0.03% Tacrolimus dermatologic ointment in the treatment of Vernal keratoconjunctivitis. Study Design: Cross-sectional. Place and Duration of Study:The study was conducted at Eye Donors Association Hospital, Wah Cantonment from August 2019 to January 2020. Materials and Methods: 103 diagnosed patients ofvernal keratoconjunctivitis, aged 3-16 years, were included in this study. They were treated with 0.03% Tacrolimus dermatologic ointment,applied in the inferior fornix once at night time, for a period of two months. In addition, these patients were also prescribeda topical antihistamine (0.05 % ketotifen eye drops 3 times a day)and preservative free artificial tearsfor symptomatic relief. The patients were evaluated at 4 and 8 weeks after the initiation of treatment. At each follow up the clinical signs were assessed on a slit lamp biomicroscope by a single observer and recorded on a standardized grading sheet. Results: Out of 103 patients, 66% were male and mean age was 9 years (range 3-16 years). The mean baseline scores showed a statistically significant decrease, with the exception of palpebral follicles & limbal Trantas dots after 8 weeks of treatment. Conclusion: 0.03% Tacrolimus dermatologic ointment was found to be safe and effective in the treatment of vernal kerato-conjunctivitis.